Literature DB >> 16470355

[Late effects after chemotherapy].

W Pönisch1, D Niederwieser.   

Abstract

Today, about 60% of adult patients and 80% children diagnosed with cancer will survive 5 years after diagnosis. Approximately two thirds of cancer survivors will experience at least one late effect, and about one third severe or life threatening late effects. The aim of cancer treatment today is to cure the malignant disease but at the same time, to minimize the incidence of post-treatment complications. In the current overview we summarize, based on the most recent publications, typical late effects in cancer survivors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470355     DOI: 10.1007/s00108-006-1577-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  20 in total

1.  Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation.

Authors:  J Pihkala; U M Saarinen; U Lundström; K Virtanen; K Virkola; M A Siimes; E Pesonen
Journal:  Eur J Cancer       Date:  1996-01       Impact factor: 9.162

2.  Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.

Authors:  Gianni Bonadonna; Simonetta Viviani; Valeria Bonfante; Alessandro M Gianni; Pinuccia Valagussa
Journal:  Eur J Cancer       Date:  2005-02-24       Impact factor: 9.162

3.  The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group.

Authors:  A Locasciulli; M Testa; M G Valsecchi; A Bacigalupo; S Solinas; J F Tomas; P Ljungman; A Alberti
Journal:  Transplantation       Date:  1999-11-27       Impact factor: 4.939

4.  Cardiovascular abnormalities in long-term survivors of childhood malignancy.

Authors:  S E Lipshultz; S E Sallan
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

Review 5.  Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

Authors:  Kate McKeage; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems.

Authors:  L Adès; P Guardiola; G Sociè
Journal:  Blood Rev       Date:  2002-06       Impact factor: 8.250

7.  The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.

Authors:  Steven E Lipshultz; Nader Rifai; Virginia M Dalton; Donna E Levy; Lewis B Silverman; Stuart R Lipsitz; Steven D Colan; Barbara L Asselin; Ronald D Barr; Luis A Clavell; Craig A Hurwitz; Albert Moghrabi; Yvan Samson; Marshall A Schorin; Richard D Gelber; Stephen E Sallan
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

8.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

9.  Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Authors:  Sandra M Swain; Fredrick S Whaley; Michael S Ewer
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

10.  Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia.

Authors:  Massimo Franchini; Giorgio Gandini; Dino Veneri; Giovanna de Matteis; Francesca Federici; Pietro Solero; Giuseppe Aprili
Journal:  Transfusion       Date:  2004-06       Impact factor: 3.157

View more
  3 in total

1.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11

2.  CYP1B1 as a therapeutic target in cardio-oncology.

Authors:  Alexa N Carrera; Marianne K O Grant; Beshay N Zordoky
Journal:  Clin Sci (Lond)       Date:  2020-11-13       Impact factor: 6.124

3.  The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy.

Authors:  Urszula Demkow; Beata Biatas-Chromiec; Anna Stelmaszczyk-Emmel; Elzbieta Radzikowska; Elzbieta Wiatr; Piotr Radwan-Rohrenschef; Monika Szturmowicz
Journal:  EJIFCC       Date:  2011-03-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.